Aquestive Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Aquestive Therapeutics, Inc. (AQST) reported Capital Expenditures Incurred but Not yet Paid of $43.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- Aquestive Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $12.00K, a 84.62% decline year-over-year.
- Aquestive Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$43.00K.
- Aquestive Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was $78.00K.
- Aquestive Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $0.00.
- Aquestive Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $52.00K, a 33.33% decline from fiscal 2024.
- Aquestive Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $78.00K.
- Aquestive Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$31.00K derived: sum of 2 quarters · filed 2026-03-04 | $52.00K 10-K · filed 2026-03-04 | |
| 2025-09-30 | -$43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $40.00K 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $83.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $78.00K derived: sum of 2 quarters · filed 2026-03-04 | $78.00K 10-K · filed 2026-03-04 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |